Diabetes drives the nation's costliest chronic disease burden, and retinopathy affects most patients over time. The panel outlines the scale of DME and why its economic consequences extend well beyond the eye clinic.
The Economics of Extended-Interval Dosing in Diabetic Macular Edema: Insights From the PHOTON Cost Analysis
Anti-VEGF therapy remains the standard of care for center-involved DME, yet eye care competes with dialysis, amputations, and other demands. Dr. Patel explains how disease severity should guide scheduling priority.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
5 things you should know about the midterms and healthcare
2
Labor Department rule ushers in a new era of PBM transparency for self-insured employers
3
2.3 million reasons to rethink member communications before Jan. 1
4
Combining EHR, claims and outside death data captures most cancer deaths in real-world database | AMCP Nexus 2026
5